Provide feedbackProvide feedback

Home :: Urology

Vasectomy not associated with prostate cancer risk, study shows

Tuesday, November 18 2008 | Comments
Evidence Grade 3 What's This?

No association was seen between vasectomy and the risk of prostate cancer, including associations between prostate cancer and age at vasectomy, according to recently published study results. In the early 1990s, a positive association between vasectomy and prostate cancer was reported, but subsequent studies did not confirm this relationship, although there were suggestions of an association in subgroups such as men who undergo vasectomy at a younger age or when several decades have passed...

No association was seen between vasectomy and the risk of prostate cancer, including associations between prostate cancer and age at vasectomy, according to recently published study results.

In the early 1990s, a positive association between vasectomy and prostate cancer was reported, but subsequent studies did not confirm this relationship, although there were suggestions of an association in subgroups such as men who undergo vasectomy at a younger age or when several decades have passed since the procedure, the authors explained. These later studies, however, had limitations because of the short intervals between exposure and disease since vasectomy only became widely used in the 1960s and the generally long latency period of prostate cancer, they added.

To address this issue in more detail, the researchers conducted a population-based prostate cancer case-control study in 1,001 men who received a diagnosis of prostate cancer from Jan. 1, 2002 to Dec. 31, 2005, in the Seattle-Puget Sound region and 942 matched controls.

The odds ratios (ORs), as an estimate of the relative risk of prostate cancer associated with various vasectomy parameters, were calculated using unconditional logistic regression. Parameters examined included age at vasectomy, years since vasectomy, and vasectomy year.

Results show that the prevalence of vasectomy was similar in cases and controls (36.2% vs 36.1%; adjusted OR, 1.0; 95% CI, 0.8-1.2). In addition, no associations were seen between prostate cancer and age at vasectomy, years elapsed since vasectomy, or calendar year of vasectomy.

No suggestion of effect modification by age, race, or family history or history of benign prostatic hyperplasia was seen either. Polytomous regression risk estimates also did not differ by clinical parameters such as Gleason score, serum prostate-specific antigen, and cancer stage.

"These findings indicate there is no association between vasectomy and risk of prostate cancer," the authors concluded. "In addition, we did not find evidence of increased risk of prostate in younger men who had undergone vasectomy or in men with extended periods of time since undergoing the procedure." (Holt S, et al. J Urol 2008;180:2565-2568.)

Latest News

Naftopidil improves nocturia after failure of tamsulosin, data reveal Verusmed

Tuesday, November 18 2008 | Comments
Evidence Grade 3 What's This?
In patients with benign prostatic hyperplasia (BPH) who failed to respond to tamsulosin and whose main complaints are storage and voiding or who have a low compliance bladder and detrusor overactivity, naftopidil improves nocturia and urinary flow rate, according to study data.

The researchers conducted a study to examine the clinical usefulness of naftopidil in 122 patients with BPH complaining of nocturia >=3 times, mainly because of reduced bladder capacity, as well as...

PSA velocity associated with, prostate cancer aggressiveness, Gleason score, study shows Verusmed

Tuesday, November 18 2008 | Comments
Evidence Grade 2 What's This?
Prostate-specific antigen velocity (PSAV) is a valid marker for prostate cancer aggressiveness and is a significant independent predictor of Gleason score and non-organ-confined disease in the radical prostatectomy specimen, new data reveal.

Although Gleason score is linked to treatment outcomes, sampling errors and the large number of men treated with radical prostatectomy whose scores are updated in the specimen, result in the need for other variables to identify cancers that...
Tags: Prostate Cancer


Statin use appears to lower PSA levels, study shows Verusmed

Tuesday, November 18 2008 | Comments
Evidence Grade 3 What's This?
After the initiation of statin treatment, prostate-specific antigen (PSA) levels declined by a statistically significant amount, a finding that could complicate cancer detection if confirmed in other studies, according to recently published data.

The effect of statin use on prostate cancer is a controversial topic, with studies showing mixed and conflicting results, the authors explained. The effect of statins on PSA levels, however, has only been examined in one other small...
Tags: Prostate Cancer, Prostate Cancer


Solifenacin reduces urgency, increases warning time in patients with OAB, late-stage data show Verusmed

Tuesday, November 18 2008 | Comments
Evidence Grade 2 What's This?
Treatment with solifenacin succinate significantly reduced episodes of urgency and significantly improved warning time as compared with placebo in patients with overactive bladder (OAB), according to recently published data.

The double-blind Phase III Vesicare Efficacy and Safety in Patients with Urgency Study (VENUS) included 739 patients with OAB. Patients were randomized to receive solifenacin or placebo for 12 weeks. For the first 4 weeks, solifenacin 5 mg was used. After...